Vascular-endothelial-growth-factor-C antagonistic polypeptide and application thereof

Abstract

The invention relates to the field of drugs, in particular to polypeptide for suppressing vascular endothelial growth factors C and treating the acute lymphocytic leukemia. The sequence of the polypeptide is NHISTPQCQGLSKPHKITV and is a brand new sequence. By means of the polypeptide, the vascular endothelial growth factors C can be suppressed out of a body at a 1-micromole level, the tumor-bearing mice survival rate can be increased in an in-vivo test, and the potential new drug development value is achieved.

Description

technical field [0001] The invention relates to vascular endothelial growth factor C antagonistic polypeptide and application thereof, in particular to a polypeptide capable of inhibiting vascular endothelial growth factor C for treating acute lymphocytic leukemia. Background technique [0002] Acute lymphoblastic leukemia (ALL) is a progressive malignant disease characterized by large numbers of immature white blood cells that resemble lymphoblasts. These cells can be found in the blood, bone marrow, lymph nodes, spleen and other organs. Acute lymphoblastic leukemia accounts for 80% of acute leukemia in children, and the peak incidence is between 3 and 7 years old. The greatest threat to patients with ALL is spread and metastasis. How to eliminate distant metastasis of a certain cancer or prevent recurrence is an indispensable part of cancer treatment, and it is also a hot issue in the treatment of acute lymphoblastic leukemia currently being discussed. [0003] Lymph is...

AI Technical Summary

Problems solved by technology

[0005] Currently, there is no well-developed vascular endothelial growth factor-C antagonistic polypeptide available for the treatment of acute lymphoblastic leukemia